Confluent (CFLT) Q2 Revenue Jumps 20%
GAAP revenue rose 20% year over year to $282.3 million in Q2 2025, surpassing consensus GAAP revenue estimates by $3.9 million.
Non-GAAP earnings per share reached $0.09, beating expectations and up 50.0% year over year.
Confluent Cloud revenue climbed 28% year over year, but management issued cautious guidance due to consumption trends among large customers.
These 10 stocks could mint the next wave of millionaires ›
Confluent (NASDAQ:CFLT), the data streaming platform behind much of the modern real-time data movement in business, reported its results for the second quarter of fiscal 2025 on July 30, 2025. The most notable news was continued solid revenue growth and margin improvement, with second-quarter revenue coming in at $282.3 million -- 20.0% higher than the prior-year quarter and ahead of analysts' expectations. Subscription revenue reached $270.8 million and non-GAAP earnings per share were $0.09, both exceeding consensus estimates. Confluent also improved its operating margin significantly compared to last year.
However, management guided cautiously for the next quarter, reflecting more conservative expectations on large customer cloud spending. Overall, the period showed momentum in cloud adoption and new product traction, tempered by a prudent stance on near-term growth projections.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Company Overview and Business Drivers
Confluent is a data infrastructure company focused on enabling real-time data streaming for businesses of all sizes. Its core product is a data streaming platform that allows companies to move and process information quickly and reliably, supporting a wide range of applications, from fraud detection in banking to supply chain management in retail.
The business is anchored in open-source technologies, particularly Apache Kafka, which its founders helped create. Over time, Confluent has expanded the platform to include cloud-native offerings (Confluent Cloud), on-premises deployment (Confluent Platform), real-time data processing with Apache Flink for stream analytics, and newer tools like Tableflow. It supports flexible deployment -- cloud, on-premises, and hybrid -- making it attractive for diverse enterprise needs. Key success factors include broad adoption of open-source technologies, responding to the rise of artificial intelligence (AI), and strong partnerships with top cloud vendors.
Quarter Highlights: Financial and Strategic Performance
The period saw several notable financial developments. Total GAAP revenue grew by 20%, while Subscription revenue climbed 21% year over year. The managed cloud service, Confluent Cloud, posted revenue growth of 28% year over year. This outpaced overall company growth and highlights ongoing adoption of managed cloud data streaming by enterprise customers. Non-GAAP operating margin improved to 6.3%, reflecting significant operating leverage compared with a near break-even margin in the same quarter last year. Adjusted free cash flow also improved to $11.0 million.
Profitability moved in a positive direction: non-GAAP operating income rose from $1.3 million in the prior-year period to $17.8 million, and non-GAAP operating margins climbed 5.7 percentage points. GAAP net loss per share narrowed modestly. The company reported $18.1 million in net cash provided by operating activities, up from $8.6 million a year ago. Stock-based compensation remained substantial at $106.9 million, roughly 37.9% of revenue.
The customer base continued to expand, with customers generating more than $100,000 in annual recurring revenue rising 10% to 1,439. Large customer wins remain a central part of the company's scaling efforts, and management noted a 'record quarter' for new customer adds in recent years, with 340 net new customers added in the first quarter. International sales, and especially deals through strategic partners and original equipment manufacturer (OEM) channels, contributed to the resilience of noncloud segments, complementing the company's core cloud growth.
Product development and strategic initiatives gained traction. Real-time stream processing, powered by Apache Flink (now integrated into both cloud and on-premises stacks), saw annual recurring revenue (ARR) grow about threefold over the past two quarters. Tableflow, a tool for simplifying table-based data pipelines, was recently released as generally available on Amazon Web Services (AWS) and received strong customer interest. Both new products are still in the early stages of adoption, so management was cautious about forecasting major financial impact in the near term.
Looking Forward: Guidance and Watch Points
Looking ahead, management offered a carefully constructed outlook for the next quarter and the full fiscal year. Subscription revenue for Q3 2025 is expected to be between $281 million and $282 million. The company projects a non-GAAP operating margin of approximately 7% for Q3 2025, and non-GAAP earnings per share of $0.09 to $0.10. For FY2025, the outlook is subscription revenue between $1.105 billion and $1.11 billion, non-GAAP operating margin of approximately 6%, and non-GAAP net income per diluted share of about $0.36.
Management emphasized a cautious approach to guidance, reflecting observed optimization behavior among large cloud customers in the first quarter and April 2025, who are slowing new use case adoption and focusing more on cost control. Unlike previous periods of quick rebound, current guidance assumes a slower or flat pace in large customer consumption. Smaller customer behavior and the pipeline for new customers remain healthy, according to management.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,049%* — a market-crushing outperformance compared to 182% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of July 29, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
16 minutes ago
- CTV News
U.S. to initially impose ‘small tariff' on pharma imports, Trump says
President Donald Trump talks to reporters on the South Lawn of the White House before he boards Marine One en route to Joint Base Andrews, Md., Friday, Aug. 1, 2025, in Washington. (AP Photo/Mark Schiefelbein) WASHINGTON — U.S. President Donald Trump said on Tuesday that the United States would initially place a 'small tariff' on pharmaceutical imports before hiking it to 150 per cent within 18 months and eventually to 250 per cent in an effort to boost domestic production. 'In one year, one and a half years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country,' Trump told CNBC in an interview. He did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200 per cent. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at '25 per cent or higher,' rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the 'next week or so,' but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. Several drugmakers have pledged multibillion-dollar investments in U.S. manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing US$50 billion to expand its American operations. PhRMA, the main lobbying group for the industry, did not immediately respond to a request for comment. A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15 per cent. --- Reporting by Patrick Wingrove in New York, Andrea Shalal in Washington and Bhargav Acharya in Toronto; Editing by Doina Chiacu and Mark Porter
Globe and Mail
16 minutes ago
- Globe and Mail
UBS to Pay $300M to Settle Credit Suisse Mortgage Securities Lawsuit
UBS Group AG UBS has agreed to pay $300 million to the United States Department of Justice (DOJ) to resolve a legacy matter related to the mis-selling of mortgage-linked investments by Credit Suisse in the United States. On Aug. 1, 2025, Credit Suisse Securities (USA) LLC agreed to settle all Credit Suisse's outstanding consumer relief obligations under the 2017 settlement for its residential mortgage-backed securities (RMBS) business. History of the UBS Lawsuit In January 2017, Credit Suisse reached a $5.28 billion settlement over its role in selling residential mortgage-backed securities between 2005 and 2007. The agreement required the bank to pay $2.48 billion as a civil penalty to the U.S. government, along with $2.8 billion in relief measures such as loan modifications for struggling homeowners, debt forgiveness and funding for affordable housing initiatives. The 2017 settlement was part of a broader initiative by the U.S. authorities to hold major banks accountable for their involvement in the 2007–2008 financial crisis. The DOJ raised allegations that Credit Suisse knowingly acquired and securitized low-quality mortgage loans while misleading investors about the associated risks of these securities. In the years leading up to the crisis, many large banks engaged in misconduct related to RMBS. The DOJ ultimately collected roughly $36 billion in civil penalties from 18 financial institutions for RMBS-related fraud during that period. UBS resolved its own RMBS case with the DOJ in August 2023, agreeing to pay about $1.44 billion in a civil penalty, roughly four months after it acquired Credit Suisse in a $3.25 billion government-orchestrated deal. Other Regulatory Probes Faced by UBS In May 2025, UBS agreed to pay $511 million to resolve a tax probe by the U.S. DOJ against Credit Suisse for preparing false income tax returns and tax evasion. The two-year investigation by the DOJ, initiated before UBS acquired Credit Suisse, found that Credit Suisse aided and assisted in tax evasion through its 475 offshore accounts to prepare false tax returns to conceal more than $4 billion from the US Internal Revenue Service (IRS). The DOJ reported that most of this misconduct occurred between 2014 and June 2023. Thus, an increase in claims against the company and regulatory fines over Credit Suisse's dealings is expected to increase litigation provisions in the near term. Over the past six months, UBS Group shares have gained 11.9% compared with the industry 's 17.6% rise. UBS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Litigations Faced by Other Finance Firms Last month, CNBC reported that Robinhood Markets, Inc. HOOD is under investigation by Lithuania's central bank, its lead regulator in the European Union (EU), regarding its newly launched tokenized equity products. The scrutiny follows Robinhood's recent launch of its Stock Tokens product across the EU, aimed at offering blockchain-based tokenized access to shares, including those of private firms. The offering sparked immediate questions from OpenAI, which openly distanced itself from HOOD's product. Robinhood defended the tokens by highlighting that they are backed by ownership interests designed to provide investors with indirect exposure to private markets. Nonetheless, regulators remain wary, specifically regarding the transparency and legality of how these digital instruments are offered to retail investors. In June, in a ruling, Anthony Trenga, U.S. District Judge in Alexandria, VA, announced that Capital One COF will have to face a lawsuit by social media creators who claim that the bank's free browser extension deprived them of commissions on sales generated through their content. According to the creators, the Capital One Shopping browser extension, which has more than 10 million users, is used to discover discounts. It erroneously reflected Capital One as the source of referral traffic at checkout, making it appear as if consumers had clicked the bank's referral links before making purchases. The creators alleged that this enabled Capital One to collect millions of dollars in commissions that rightfully belonged to bloggers, influencers, YouTubers and other content creators. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> UBS Group AG (UBS): Free Stock Analysis Report Robinhood Markets, Inc. (HOOD): Free Stock Analysis Report
Globe and Mail
16 minutes ago
- Globe and Mail
These 3 CEOs Just Bought the Dip
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. But it's critical to note that insiders have a longer holding period than most, and many strict rules apply to their transactions. Recently, CEOs of several companies – MSCI (MSCI), Charter Communications (CHTR), and Healthpeak Properties (DOC) – have made splashes, acquiring shares. Let's take a closer look at the transactions for those interested in trading like the insiders. MSCI CEO Buys Millions Worth MSCI provides investment decision support tools, including indexes; portfolio construction and risk management products and services; Environmental, Social and Governance (ESG) research and ratings; and real estate research, reporting and benchmarking offerings. The stock is a Zacks Rank #2 (Buy) thanks to positive EPS revisions, with analysts taking expectations higher across the board over recent months. Henry Fernandez, CEO, recently has purchased roughly 12.5k MSCI shares, with the total transaction totaling roughly $6.7 million. As shown below, the purchase aligned with a dip in MSCI shares, reflective of confidence in the positive EPS and broader long-term outlook. CHTR CEO Dives In Charter Communications is the second-largest cable operator in the United States and a leading broadband communications company providing video, internet, and voice services. CEO Christopher Winfrey recently purchased roughly 3.6k CHTR shares at a total transaction value of just over $1 million. As shown below, the purchase coincided with a plunge in CHTR shares, with the CEO scooping up shares at a discounted level. X Still, analysts have lowered their EPS outlooks across the board, likely reflective of further short-term pain ahead. Positive EPS revisions would be key for a positive turnaround in sentiment, with the CEO's long holding horizon an obvious advantage here. Healthpeak CEO Buys Healthpeak Properties is a REIT in the United States that acquires, develops, manages, sells, and leases a diverse portfolio of healthcare real estate-related properties. Insiders have regularly bought on share weakness in 2025, as we can see in the green arrows in the chart below. X CEO Scott Brinker recently swooped in and purchased roughly 6k DOC shares at a total transaction value of roughly $100k. He now owns more than 210k shares overall. The stock's weak performance has been partly driven by negative earnings estimate revisions, currently a Zacks Rank #4 (Sell). The purchases here are relatively unsurprising, given the CEO's long-term horizon and the discount that shares are currently displaying. However, near-term performance can be expected to remain soft given the cloudy EPS outlook. Bottom Line Many investors closely monitor insider buys, looking to receive insights into the longer-term picture. The transactions shouldn't be relied on for near-term performance, as insiders' holding periods are longer than most, and many strict rules apply. Rather, investors can see insider buys as an overall net positive concerning the longer-term outlook. All large-cap stocks above – Healthpeak Properties DOC, MSCI MSCI, and Charter Communications CHTR – have seen recent insider activity. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> MSCI Inc (MSCI): Free Stock Analysis Report
